Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°¡¿Í»ç³¢ º´¿¡ ÇÕº´µÈ °£±â´É ÀÌ»ó¼Ò°ß¿¡ ´ëÇÑ ÀÓ»óÀû ¹× º´¸®Á¶Á÷ÇÐÀû ¼Ò°ß Clinical and Histopathologic Findings on the Abnormal Liver Function Complicated with Kawasaki Disease

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2000³â 3±Ç 1È£ p.47 ~ 55
À̼ºÃ¶, ³ª¼ÛÀÌ, Â÷ÇÑ, ½Å¹Ì°æ, ¹ÚÈ£Áø, ±èÈñ¼·,
¼Ò¼Ó »ó¼¼Á¤º¸
À̼ºÃ¶ ( Lee Sung-Chul ) 
¼­¿ï Àû½ÊÀÚº´¿ø ¼Ò¾Æ°ú

³ª¼ÛÀÌ ( Na Song-Yi ) 
¼­¿ï Àû½ÊÀÚº´¿ø ¼Ò¾Æ°ú
Â÷ÇÑ ( Tchah Hann ) 
¼­¿ï Àû½ÊÀÚº´¿ø ¼Ò¾Æ°ú
½Å¹Ì°æ ( Shin Mi-Kyeong ) 
¼­¿ïÀû½ÊÀÚº´¿ø Çغκ´¸®°ú
¹ÚÈ£Áø ( Park Ho-jin ) 
¼­¿ï Àû½ÊÀÚº´¿ø ¼Ò¾Æ°ú
±èÈñ¼· ( Kim Hee-Sup ) 
¼­¿ï Àû½ÊÀÚº´¿ø ¼Ò¾Æ°ú

Abstract

1991³â 1¿ù 1ÀϺÎÅÍ 1998³â 12¿ù 31ÀϱîÁö ¼­¿ïÀû½ÊÀÚº´¿ø ¼Ò¾Æ°ú¿¡ ÀÔ¿øÇÏ¿© °¡¿Í»ç³¢ º´
À¸·Î Áø´Ü ¹Þ¾Ò´ø ȯ¾Æ Áß Àǹ«±â·ÏÀ» ¿ÏÀüÈ÷ È®ÀÎÇÒ ¼ö ÀÖ¾ú´ø 98¸í °¡¿îµ¥ °£±â´É ÀÌ»ó¼Ò
°ß(ALT>30 IU/L)À» º¸ÀÌ°í HAV, HBV, HCV ¹× CMV, EBvirus µîÀÇ viral marker°¡ À½
¼ºÀÎ 34¸íÀ» ´ë»óÀ¸·Î ÁÖ¿ä ÀÓ»ó¼Ò°ß ¹× ±âº» °Ë»ç ¼Ò°ß°ú 4¿¹¿¡¼­ °£Á¶Á÷ »ý°ËÀ» ÅëÇÑ º´
¸®Á¶Á÷ÇÐÀû ¼Ò°ßÀ» Á¶»çÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù.
1) °¡¿Í»ç³¢ º´À¸·Î Áø´Ü¹ÞÀº ȯ¾Æ Áß °£±â´É ÀÌ»ó(ALT>30 IU/L)À» º¸ÀΠȯ¾Æ´Â 34¿¹
(34.7%)¿´À¸¸ç ³²³àÀÇ ºñ´Â 2.4 : 1À̾ú°í 5¼¼ ¹Ì¸¸ÀÌ 31¿¹(91.2%)·Î ´ëºÎºÐÀ» Â÷ÁöÇÏ¿´´Ù.
2) Æò±Õ ¹ß¿­±â°£Àº 8ÀÏ, Æò±Õ Àç¿ø±â°£Àº 9ÀÏÀ̾úÀ¸¸ç Æò±Õ ȸº¹±â°£Àº 13ÀÏ·Î ¸ðµÎ ÇÑ´Þ
À̳»¿¡´Â ȸº¹µÇ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
3) ÀÔ¿ø ´ç½Ã ¹éÇ÷±¸ Áõ°¡Áõ(>10,000/§§)Àº 26¿¹(76.0%)¿´À¸¸ç Ç÷¼ÒÆÇ Áõ°¡Áõ(>450,000/§§)
°ú ºóÇ÷ (<10 gm/dl)Àº °¢°¢ 7¿¹(20.6%)¿¡¼­ °üÂûµÇ¾ú°í C-¹ÝÀÀ¼º ´Ü¹éÀº 31¿¹(91.2%)¿¡¼­
¾ç¼ºÀ» º¸¿´´Ù.
4) ´ã³¶ÀÇ ÀÌ»ó(GB hydrops ¹× cholecystitis)Àº 3¿¹(8.8%)¿¡¼­ ³ªÅ¸³µÀ¸¸ç ½ÉÀüµµÀÇ ÀÌ»ó
¼Ò°ßÀº 1¿¹(2.9%)¿¡¼­ ÀÖ¾ú°í °ü»óµ¿¸ÆÀÇ ÀÌ»ó(dilatation ¹× aneurysm)Àº 2¿¹(5.8%)¿¡¼­ ¹ß
°ßµÇ¾ú´Ù.
5) °£ »ý°ËÁ¶Á÷À» ÅëÇÑ º´¸®Á¶Á÷ÇÐÀû ¼Ò°ß»ó °£¹®¸Æ ºÎÀ§¿¡ ¸²ÇÁ±¸°¡ ¾à°£ °üÂûµÇ°í ´ã°üÀÇ
°æÇÑÁõ½Ä ¿Ü¿¡´Â °£Á¶Á÷ ¼Õ»ó¿¡ ´ëÇÑ Æ¯À̼ҰßÀº º¸ÀÌÁö ¾Ê¾Ò´Ù.
°¡¿Í»ç³¢ º´¿¡ ÇÕº´µÈ °£±â´É ÀÌ»ó¼Ò°ßÀ» º¸ÀΠȯ¾ÆµéÀÇ ºóµµ°¡ ³·Áö´Â ¾Ê¾ÒÀ¸³ª ALTÄ¡
»ó½Â°ú ÀÓ»ó¼Ò°ß ¹× ±âº» °Ë»ç¼Ò°ßµé°ú À¯ÀÇÇÑ »ó°ü°ü°è´Â ¾ø¾úÀ¸¸ç ¿¹ÈÄ´Â ¾çÈ£ÇÑ °ÍÀ¸·Î
³ªÅ¸³µ´Ù. ±×·¯³ª °¡¿Í»ç³¢ º´ÀÇ ÀÓ»óÀû Ư¼ºµéÀ» °í·ÁÇÏ¿© °£±â´É ÀÌ»ó ȯ¾ÆÀÇ Ä¡·á¿¡ ¼Ò
ȦÈ÷ Çؼ­´Â ¾ÈµÈ´Ù°í »ý°¢µÈ´Ù.

Purpose : The aim of this research is to examine the abnormal liver function
complicated with Kawasaki disease (KD) and to analyze its clinical characteristics and
complications.

Methods : Ninty eight cases were diagnosed as having KD, among which thirty four
cases had abnormal alanine aminotransferase (ALT) (>30 IU/L). These abnormal ALT
cases were evaluated in terms of age and sex distribution, major symptoms,
complications, laboratory and histopathologic findings.

Results : Male to female ratio was 2.4 : 1 and most patients (91.2%) were under 5
years of age. Cervical lymphadenopathy was observed in 3 cases (8.8%); and recurred
cases were two (5.8%). Average fever duration was 8 days: average length of
hospitalization was 9 days; and average recovery period was 13 days. Immediately after
admission, positive CRP was observed in 31 cases (91.2%), leukocytosis (>10,000/§§) in
26 cases (76.0%), thrombocytosis (>450,000/§§) in 7 cases (20.6%), and anemia (<10
gm/dl) in 7 cases (20.6%), respectively. GB hydrops or cholecystitis were noted in 3
cases (8.8%) abnormal ECG finding in 1 case (2.9%), coronary dilatation or aneurysm in
2 cases (5.9%). Liver biopsy was done in four cases and revealed mild infiltration of
lymphocytes on the portal area and mild bile duct proliferations.

Conclusion : The abnormal liver function was noted in 34.7% of KD patients, and
subsided all within one month. But the liver function test should be checked closely in
patients of the abnormal liver function test complicated with KD despite of its good
prognosis.

Å°¿öµå

Kawasaki disease; Alanine aminotransferase (ALT); Histopathologic findings;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS